Medical-industry, a professional Medical business Platform for global enterprises and buyers.

This is a platform which collects all excellent Medical businesses in the world and wholly displays the development and features of Medical business.

We supply Medical marketing service, and help global buyers to have a better knowledge and to establish a cooperative relationship.

The best choice of global Medical trading with the world
We integrate China government resources, regional industries resources and multiple social resources and fully support the development of Medical import and export enterprises.

We provide advanced integrative marketing techniques to display Medical businesses professionally and scientifically to global buyers. By this, we can wholly promote the enterprise brand image and unique advantages and help businesses surpass their rivals.

We can provide the governmental evaluation and recommendation to upgrade enterprise credit standing and promote the success of business.

Not only supply good service but also focus on the quality.
We have professional operating team and service team to provide all-around international quality service.

We can provide professional regional procurement services for global buyers and group buying services. Consequently we can help them to save cost and reduce risks.

A professional window for exchanges between China Medical suppliers and global buyers.

Acme Machinery is seeking to supply local companies in Swaziland, Southern Africa with printing and paper box making machinery. The company, which manufactures paper printing and converting machinery, has sought the assistance of the Swaziland Investment Promotion Authority (SIPA) to help it develop its brand as well as solicit potential buyers.

Hemang Shah, MD, Acme Machinery said that ACME was immensely popular with the packaging industry in India as well as abroad, having started operations in 1961. It started off by catering mainly to varied printing press and later to the packaging industry as well, around India.

"The company has rapidly expanded the product range along with the infrastructure for manufacturing facility, with the help of top grade engineering practices and stringent quality standards as a hallmark of its products and Acme has earned various prestigious national awards," he added.

Arno G. Motulsky, MD, ScD, FACMG, Professor Emeritus (Active), Departments of Medicine (Medical Genetics) and Genome Sciences, University of Washington, Seattle, and a pioneer in the field of medical genetics, was presented with the American College of Medical Genetics Foundation (ACMGF) inaugural Lifetime Achievement Award. Dr. Motulsky was recognized for his decades of contributions to genetic medicine and as a founder of the field of pharmacogenetics. Presented the award at the 2009 ACMG Annual Clinical Genetics Meeting in Tampa, Florida, Dr. Motulsky was cheered by colleagues, former students, friends and family. Attendees from more than 25 countries participated in the event.

The new ACMG Foundation Lifetime Achievement Award is the Foundation's highest honor and recognizes an individual who has demonstrated outstanding leadership in the field of medical genetics and who exemplifies the highest standards of the profession over a lifetime.

Born in 1923, Dr. Motulsky is known as one of the fathers of modern human genetics, a renowned researcher and teacher, an outstanding mentor, editor, prolific author, collaborator, and as a soft-spoken and intellectually penetrating individual with a strong sense of social justice and ethics.

"Dr. Motulsky epitomizes the highest values of our profession. His tireless efforts to mentor, teach, research and guide have made a lasting and global impact on our field, and he has served as a role model for young people entering the profession over many decades. He has trained and inspired a tremendous number of geneticists," said R. Rodney Howell, MD, FACMG, president of the American College of Medical Genetics Foundation.

Charles J. Epstein, MD, FACMG and one of Dr. Motulsky's first fellows in the early 1960s added, "Dr. Motulsky was one of the first people in the world to start a clinical division of medical genetics, at the University of Washington, in 1957. Along with the late Dr. Victor McKusick, he is indeed the co-father of modern medical genetics. Arno's unwavering commitment as an editor, teacher, lecturer, researcher and author enabled him to set the tone for how clinical genetics is now practiced. He trained an entire generation of geneticists and always set a fine example for students … he showed them how to listen and to use what resources and knowledge they had to move forward on behalf of their patients. He is still remarkably active and is as much intellectually engaged in genetics now as he ever was. No one has a broader grasp of human and medical genetics today."

On receiving the award, Dr. Motulsky said, "I very much appreciate receiving this new award from the organization that represents all facets of clinical genetics." In regards to the future of genetics, Dr. Motulsky said, "Our knowledge of genetics and molecular biology is mounting rapidly and applications for diagnosis, prevention and treatment of genetic diseases already exist or are on the horizon. To fully achieve the promise of our science that is often exaggerated by the public media, more research and clinical investigations are required. The American College of Medical Genetics, its members and supporters play a key role in this work."

Born in Germany and a Holocaust survivor, Dr. Motulsky endured many hardships as a teenager during World War II including a difficult and desperate passage on the S.S. St. Louis, a ship that was meant to bring refugees to asylum in Cuba but was turned away and sent back to Europe. Following confinement in a succession of French internment camps, he was able to secure a visa to the United States and served in the U.S. Army from 1943-46 and 1951-53. Starting with pre-med classes at night school, he studied at Yale and then earned his Bachelor of Science and Doctor of Medicine degrees, the latter with high honors, from the University of Illinois in Chicago. He completed post-doctoral work at Michael Reese Hospital in Chicago and Walter Reed Army Medical Center in Washington D.C., Dr. Motulsky joined the faculty of the University of Washington, Seattle, in 1953, and had an illustrious and remarkable career there. A participant in high level national committees, an elected member to the National Academy of Science, Institute of Medicine, American Academy of Arts and Sciences, and the American Philosophical Society, a recipient of numerous awards throughout his distinguished career, and a member of numerous editorial boards, Dr. Motulsky has authored more than 400 articles and trained more than 70 post-doctoral students in genetics including Joseph Goldstein, MD, who later received the Nobel Prize for his work in cholesterol metabolism, work that began while he studied with Dr. Motulsky.

Amid the dire news for America's car companies comes a ray of light for beleaguered General Motors. An annual value study released Monday by Vincentric, an auto-industry analysis firm in Bloomfield Hills, Mich., gives 10 GM models top ratings. Only one model from fellow-sufferer Chrysler, the Jeep Compass, made the cut. Ford, which has yet to require government funding to help maintain its viability, had three models that earned top billing.
Among GM's winners are several models coming to define the Detroit-based company: hybrids and trucks. GM's segment toppers include the Chevrolet Tahoe and Chevrolet Malibu hybrids and the GMC Sierra 3500, Chevrolet Silverado 1500 and Chevrolet Silverado 2500 pickups.

Amid the dire news for America's car companies comes a ray of light for beleaguered General Motors. An annual value study released Monday by Vincentric, an auto-industry analysis firm in Bloomfield Hills, Mich., gives 10 GM models top ratings. Only one model from fellow-sufferer Chrysler, the Jeep Compass, made the cut. Ford, which has yet to require government funding to help maintain its viability, had three models that earned top billing.

Among GM's winners are several models coming to define the Detroit-based company: hybrids and trucks. GM's segment toppers include the Chevrolet Tahoe and Chevrolet Malibu hybrids and the GMC Sierra 3500, Chevrolet Silverado 1500 and Chevrolet Silverado 2500 pickups.

"Hopefully what this means now is get two months to refinish this plan for reorganizing, and they'll be in a position to be viable going forward," speculates Wurster. "I think [the government] wants Chrysler to do a deal and to kind of go away," he adds.

GM joined high-value stalwarts BMW and Toyota in this year's highest Vincentric ratings. The top-rated models range from the $22,600 MINI Cooper, rated best for a subcompact car, to Toyota's $64,755 Land Cruiser, rated the best of the large premium SUVs. Toyota's 4Runner, Camry, Prius, Tacoma and Venza each win their own segments, as does BMW's M3, X6, 7-Series and 5-Series Sedan and Wagon.

Toyota and BMW both deliver the products they promise, says Jez Frampton, the CEO of Interbrand, an international consulting firm.

"Brands are promises made between companies and markets, and those promises are either fulfilled or they aren't," Frampton says. "BMW and Mercedes won't let us down. They'll show us the way for premium motoring."

Though Frampton includes Mercedez-Benz on his short list of best brands, the German automaker is conspicuously absent from the best value report. Other premium no-shows include Audi and Lexus.

"That's very notable--particularly Lexus in my viewpoint, because they had historically done pretty well," says Wurster. "But I think it's more notable that BMW was the winner in many of those categories. ... It was excellent performance from their standpoint."

Other highlights in the report are the Volkswagen Routan van and Tiguan crossover. Each has high residual values that enhance the overall value, especially the Tiguan in the growing but precarious crossover market.

The value of any vehicle relies in part on gas prices, and that affects crossovers more than most. They offer good value to consumers who would otherwise drive a large SUV, but their car-like handling with extra cargo space doesn't offer the best value for everyone.

"Smaller cars and midsize vans have made a rebound in the economy, so bigger vehicles generally are taking a hit, and I think that's because people are asking themselves, 'What do I really need?'" says Karl Brauer, the editor in chief at Edmunds.com, a car research Web site.

WASHINGTON, April 1 - Auto dealers stepped up lobbying on Wednesday for government to help them finance their inventories, while lawmakers sought to broaden support for an auto sales incentive plan worth up to $2 billion.

The National Automobile Dealers Association asked members to support a Senate petition to the Obama administration to loosen a credit logjam, improve liquidity within the sector and stem dealership closings and job losses.

The group said more than 1,000 dealers have closed this year at a cost of 50,000 jobs.

"Credit is the lifeblood of the franchised dealers' economic model. Additionally, dealers, like many other businesses, need sufficient working capital to maintain cash flow," read a draft letter from Sen. Jeanne Shaheen, a New Hampshire Democrat, to President Barack Obama.

Dealers want the administration to expand access to Small Business Administration lending to help finance their floorplans.

Additionally, the group wants the Federal Reserve to expand criteria for a recently unveiled credit program to ensure struggling auto finance companies can qualify.

The major finance units for Ford Motor Co, General Motors Corp and Chrysler LLC and overseas manufacturers provide terms for dealers to purchase vehicles they sell to consumers.

"The number of floorplan lenders has declined within the past six months and lenders still in the market are insisting on terms and conditions that are not affordable for many businesses," Shaheen's letter said.

GMAC Financial Services said separately that it would resume making car and truck loans to subprime borrowers and will lower inventory financing costs for dealers.

GM and Chrysler financing units have already received billions in government aid.

SUPPORT FOR 'CLUNKER' PLAN

Additionally on Wednesday, proposals to stimulate auto sales took shape in the House of Representatives and Senate with any final action still weeks away, lawmakers said.

Competing proposals would offer a voucher worth up to $5,000 to consumers who trade in older, less fuel efficient vehicles for new ones that get sharply higher gas mileage.

"The American auto industry is in serious jeopardy. Now is not the time to point fingers or ask how we got here. The question is what Congress can do to help jump-start these companies, save jobs and create a more fuel efficient fleet," said a joint statement from Democratic Senators Dianne Feinstein of California and Charles Schumer of New York.

U.S. auto sales remain near 30-year lows and overseas manufacturers are also struggling.

GM, which is facing possible bankruptcy, saw its U.S. sales decline by 45 percent in March, according to figures released on Wednesday, while Ford sales fell nearly 41 percent for the month. Chrysler sales fell 39 percent last month.

Lawmakers in both houses estimate the sales incentive program, called "Cash for Clunkers," would cost up to $2 billion over four years. Funds would likely come from unused money from the U.S. economic stimulus package approved by Congress in February.

President Barack Obama endorsed the idea on Monday but no new federal spending is planned.

Rep. Steve Israel assumes a sales gain of between 500,000 and 1 million cars per year under a plan he authored. Israel said the program would result in a "major reduction" in greenhouses gasses, blamed for global warming, and other pollutants.

Lawmakers were warming to a provision that would permit consumers to use vouchers for buying imported vehicles in accordance with trade agreements. Some lawmakers, especially in the House, prefer that the incentive program benefit those vehicles made in the United States.

Overseas manufacturers have concentrated on producing more efficient gasoline-only and hybrid vehicles, while U.S. companies, until recently, have focuses mainly on less efficient trucks, vans and sport utilities.

B. Braun Medical Inc. (B. Braun) said its Outlook(R) Safety Infusion System, DoseTrac(TM) Infusion Management Software and DoseLink(TM) Interfaces successfully completed applicable portions of the Healthcare Information Technology Standards Panel's (HITSP) federally recognized Interoperability Specifications test at the Integrating the Healthcare Enterprise 2009 Connectathon in Chicago in February.

The Connectathon is the healthcare information technology (IT) industry's largest interoperability testing event. More than 130 healthcare IT systems were tested by the nearly 70 vendors present.

"This is a critical achievement for B. Braun," said Scott Zaffrin, Manager, Infusion Systems Connectivity for B. Braun Medical Inc. "The emphasis in healthcare today, within the industry and the Obama Administration, is on developing integrated healthcare systems that interface with other systems and have the ability to transmit patient information electronically to reduce errors and deliver more effective treatment to patients. Our suite of infusion system products is designed to do just that."

B. Braun will demonstrate the Outlook(R), DoseTrac(TM) and DoseLink(TM) (their IHE compliant interfaces) systems and its medication administration and electronic health record interoperability at the Healthcare Information and Management Systems Society's HIMSS09 Interoperability Showcase at booth # 7750 in the North Hall of McCormick Place during the HIMSS Conference & Exhibition, April 4-9 in Chicago.

Designed as a HIMSS Health Information Exchange (HIE)- based environment, the Showcase includes clinical scenarios enabled by the standards-based IHE framework and HITSP federally recognized Interoperability Specifications.

B. Braun will demonstrate the interoperability of its DoseTrac(TM) Infusion Management Software, DoseLink(TM) Interfaces and Outlook(R) Safety Infusion Systems using two-way communication with numerous vendors including Cerner, GE Centricity, Draeger, Philips, Capsule and more.

"We look forward to the opportunity to interact with other healthcare professionals and demonstrate our solutions in the kind of clinical scenarios our customers face every day," said Zaffrin.

B. Braun Infusion Pumps deliver critical IV medications to patients and communicate infusion data to the company's DoseTrac(TM) Infusion Management Software. Infusion data is wirelessly communicated to the DoseTrac(TM) software, which collects and stores real-time infusion data allowing caregivers to view it from any workstation. Its open architecture design allows it to interface with any hospital or pharmacy information management system. DoseTrac(TM) is the only software of its type to offer both real-time displays of infusion data as well as comprehensive retrospective reporting capabilities.

About B. Braun

B. Braun is a global leader in infusion therapy and pain management and a pioneer in passive safety devices and PVC-/DEHP-free products. Every day, B. Braun employees worldwide share their knowledge with colleagues and customers to improve working processes in hospitals and medical practices and to enhance safety for patients, physicians and nurses.

Consistently recognized by Frost & Sullivan and KLAS for its medical technology and support services, B. Braun promotes best practices for continuous improvement of healthcare and, guided by its "Sharing Expertise" philosophy, helps today's healthcare workers address critical issues including environmental responsibility, medication errors reduction and infection prevention.

About HIMSS

The Healthcare Information and Management Systems Society (HIMSS) is the healthcare industry's membership organization exclusively focused on providing global leadership for the optimal use of healthcare information technology (IT) and management systems for the betterment of healthcare. Founded in 1961 with offices in Chicago, Washington D.C., Brussels, Singapore, and other locations across the United States and the globe, HIMSS represents more than 20,000 individual members and over 350 corporate members that collectively represent organizations employing millions of people. HIMSS frames and leads healthcare public policy and industry practices through its advocacy, educational and professional development initiatives designed to promote information and management systems' contributions to ensuring quality patient care.

EAST HILLS, N.Y.--(BUSINESS WIRE)--The Board of Directors of Pall Corporation (NYSE:PLL - News) today declared a dividend of $0.145 per share payable on May 8, 2009 to shareholders of record as of April 24, 2009. Pall increased its dividend in January 2009 from $0.13 to the current $0.145 per share. Based on today's closing price of $20.96 per share the dividend yield is 2.8%.

Pall Corporation is the global leader in the field of filtration, separation and purification. Pall is organized into two businesses: Life Sciences and Industrial. These businesses provide leading-edge products to meet the demanding needs of customers in biotechnology, pharmaceutical, transfusion medicine, energy, electronics, water purification, aerospace, transportation and broad industrial markets. Total revenues for fiscal year 2008 were $2.6 billion. The Company is headquartered in East Hills, New York and has extensive operations around the world.